- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Progressive fibrosing interstitial lung disease (PF-ILD)
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1371KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 415KB)
Nintedanib – March 2021
Nintedanib: Capsule 100 mg, Capsule 150 mg; Ofev®
Last updated
16 July 2021